Blood test may predict dangerous allergy to leukemia drug
NCT ID NCT07499336
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aims to understand why some children and young adults with acute lymphoblastic leukemia (ALL) develop severe allergic reactions to PEG-asparaginase, a crucial chemotherapy drug. Researchers will collect blood and bone marrow samples from 45 patients (20 with allergies and 20 without) to look for biomarkers that could predict who is at risk. The goal is to find a way to identify at-risk patients before they have a reaction, potentially making treatment safer and more effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to a simple blood test to predict which patients are at risk of allergic reactions to PEG-asparaginase, making treatment safer.
What could go wrong
This is an observational study, not a treatment trial. It is small (45 participants) and only looks for clues, so it may not lead to a usable test.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKAEMIA - CATEGORY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••